Tags : Modifiers

Genentech Signs an Exclusive Option and License Agreement with Skyhawk

Shots: Skyhawk to receive up front, more than $2B as option fee & milestones, royalties on sales and will utilize its SkySTAR technology platform to discover and develop RNA splicing modifiers targeting oncology & neurological disorders Genentech to get an exclusive WW license to develop & commercialize RNA splicing modifiers targeting neurodegenerative diseases and cancer […]Read More

Takeda Collaborates with Skyhawk Therapeutics to Develop RNA Splicing Modifiers

Shots: Skyhawk to receive upfront, milestones & royalties on sales and will discover & preclinically develop targeted therapies utilizing its SkySTAR technology. Takeda to get an exclusive WW license to develop & commercialize targeted therapies for multiple neurodegenerative diseases The focus of the agreement is to develop therapies directing central nervous system for improvement of […]Read More